REGISTRATION FEE
No registration fee is charged.

EXHIBITION
Space will be available for displays and exhibits by commercial vendors during the conference. Interested exhibitors should contact the Scientific Secretariat by 30 April 2022.

CONFERENCE SECRETARIAT
Scientific matters and paper submission
Ms Diana Paez
Ms Miriam Mikhail Lette
Nuclear Medicine and Diagnostic Imaging Section
Division of Human Health
Email: imic2022@iaea.org

Administration and organization
Ms Julie Zellinger
Conference Services Section
International Atomic Energy Agency
Vienna International Centre
PO Box 100 1400 Vienna, Austria
Tel.: +43 1 2600 21314 Fax: +43 1 2600 7
Email: Conference.Contact-Point@iaea.org

CONFERENCE WEB PAGE
Detailed information on administrative procedures including participation, submission of papers, registration and grants, is provided on the conference web page:
https://www.iaea.org/events/imic2022
Please include reference number IAEA-CN-304 in all communications.

International Conference on Integrated Medical Imaging in Cardiovascular Diseases
13 – 16 December 2022
IAEA Headquarters
Vienna, Austria

#IMIC2022
CN-304
BACKGROUND

In 2022, the International Atomic Energy Agency (IAEA) will hold the International Conference on Integrated Medical Imaging in Cardiovascular Diseases (IMIC-2022), building on the success of the IMIC-2013 and IMIC-2016 conferences. Non-communicable diseases (NCDs) are steadily increasing both in developed and developing countries. Cardiovascular diseases (CVDs) are a dominant subgroup of NCDs and account for the highest proportional mortality among all NCDs. Consequently, CVDs rank among the main priorities of health care systems of many IAEA Member States. Identifying appropriate management strategies is of the utmost importance, as it was estimated by the World Health Organization (WHO) that more than 23 million people will die annually due to CVDs by 2030. The situation is particularly alarming in low- and middle-income countries, as 80% of the mortality burden is borne by such countries.

Medical imaging, including molecular nuclear medicine, is extremely important in that it offers strategic advantages in both diagnostic and therapeutic decision-making. It provides invaluable inputs for different stages of CVD management including diagnosis, staging, treatment, prognosis and follow-up. Medical imaging includes techniques such as single photon emission computed tomography (SPECT), positron emission tomography (PET), echocardiography, computed tomography (CT) and magnetic resonance imaging (MRI). These techniques represent very useful tools to understand the pathology of individual patients in detail and can therefore serve to facilitate specifically tailored clinical management. Each imaging modality has its advantages and limitations which need to be understood properly by health care professionals dealing with CVDs. Given their clinical utility, integrating these techniques into the health care systems of Member States can provide an invaluable contribution to improving CVD management. Many Member States are already actively using, have recently implemented, or are planning to acquire relevant medical imaging techniques.

In order to follow up on the most recent advances in the use of medical imaging in the management of CVDs and to improve patient management, support professional development, and strengthen the capacities of Member States, it is proposed to hold IMIC-2022.

OBJECTIVE

The conference will cover trends spanning the spectrum of activities related to the use of nuclear medicine and diagnostic imaging in CVDs with the following objectives:

• To review the status of evidence-based recommendations for the use of different imaging modalities in the management of CVDs including SPECT, PET, echocardiography, CT and MRI;
• To review the latest advances and developments in cardiac imaging;
• To reflect on the importance and future of integrated cardiovascular imaging approaches;
• To deliver supportive ‘know-how’ via continuing medical education programmes in the field, including information on the relative merits and limitations of each imaging modality;
• To reflect on the impact of COVID-19 on the diagnosis of heart conditions, and on the role of medical imaging in the assessment of cardiovascular complications due to COVID;
• To interact with all professionals involved in the management of CVDs and provide them with state-of-the-art information on cardiac imaging; and

• To identify challenges and trends, as well as the role of the IAEA and other professional organizations in addressing these.

AUDIENCE

This conference will give an opportunity to review the exciting latest developments in the field of integrated medical imaging as applied to CVDs. The target audience comprises:

• Nuclear medicine physicians
• Radiologists
• Cardiologists
• Radiochemists/Radiopharmacists
• Medical physicists
• Technologists/Radiographers
• Other practitioners and scientists working in all aspects of cardiac imaging.

KEY DEADLINES

30 April 2022 Submission of abstracts, including Forms A and B, through the InTouch+ platform

30 April 2022 Submission of grant applications (Form C) through the InTouch+ platform

31 July 2022 Notification of acceptance of abstracts

No deadline Registration only (submission of Form A) through the InTouch+ platform